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Abstract
Coronavirus COVID-19 started in December 2019, and it has spread rapidly
across China and the whole world. In this chapter, we analyzed the number of
confirmed cases in US, India, France, Russia and Brazil. Additionally, we took into
account Latin American countries like Argentina, Colombia, Peru, Chile and Mex-
ico. We noticed, how some countries got a low death rate, despite its high number
of confirmed cases (US). Additionally, it is interesting, how some countries with a
high percentage of obesity got the highest death rate (Mexico). Also, we noticed a
decreasing number in confirmed cases after a intensive vaccination plan (US).
Finally, we evaluated Weibull Long Short-Term Memory (W-LSTM) and Multipli-
cative Trend Exponential Smoothing (MTES) to predict confirmed cases, in this
case, W-LSTM showed a more realistic forecasting.
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1. Introduction
Coronavirus COVID-19 pandemic started in December 2019 in Wuhan, China.
This virus has high viral infectivity [1], so it has spread rapidly across China and
other countries. Furthermore, 140,849,925 confirmed cases and 3,013,217 deaths
were reported in the whole world until the last April 20th [2].
This new coronavirus made huge strain on the health system around the world
forcing to establish decisions like quarantines and social distances in a effort to
contain the spread of the virus [3]. Some countries with high incomes like United
Kingdom, Italy, Spain and United States of America had to take measures such as
hiring retired health personnel to assist battle infections.
Also, countries like United States agreed with car and weapon manufacturers to
provide ventilators to help in the pandemic fight. The situation in countries with
low and middle incomes were challenged, because they already have poor and weak
health systems before COVID-19. They had limited financial resources, unavailable
medications and inadequate health personnel, also in these countries exist a gap on
the socio-economic. A person of higher socio-economic standing are more likely to
have access to quality health services and medications [4].
Since the identification of SARS-CoV-2 virus, the scientific community was
starting to develop over 300 vaccines projects, 40 of them are now on undergoing
clinical evaluation, 10 of these are in Phase III and 3 of them have passed the phase
1
III with effective outcomes. The existing data propound that the vaccine candidates
can reduce the spread of the pandemic protecting individuals. On the other hand,
the fast development of vaccines candidates carries with some unresolved issues
(only time could clarify). Moreover, technical and ethical problems were added
with the production of billions of doses [5]. Despite, there are dozens of potential
vaccine candidates [6], the herd immunity has not achieved yet.
Nowadays, the scientist communities are publishing several papers of studies
about COVID-19. For instance, a research team had published an analysis of
confirmed cases with Multiplicative Trend Exponential Smoothing (MTES) and
Long Short-Term Memory (LSTM) [7]. Nonetheless, other researchers made a
comparison with Auto-Regressive Integrated Moving Average (ARIMA), Nonlin-
ear Autoregression Neural Network (NARNN) and LSTM to predict the confirmed
cases of Denmark, Belgium, Germany, France, United Kingdom, Finland,
Switzerland and Turkey, they concluded that LSTM was the most accurate model
[8]. In addition, LSTM had been used to predict the trends and possible ended time
of COVID-19 [9]. Also, other research used LSTM to predict the cumulative
recovered, fatalities and confirmed cases [10].
In this Chapter, we analyzed the evolution of COVID-19. We took into account
countries with the major number of confirmed cases like US, India, France, Russia
and Brazil. Additionally, we took into account Latin American countries like
Argentina, Colombia, Peru, Chile and Mexico. We analyzed the evolution of
confirmed cases, deaths, the effects of vaccination and finally, we evaluated some
models to forecast the number of confirmed cases.
2. Analysis of confirmed cases and deaths
In this section, we analyzed the number of confirmed cases and deaths in some
countries. We focused on countries like US, India, France, Russia and Brazil,
because, they got the major number of confirmed cases around the world.
Additionally, we focused in the some Latin American countries like Argentina,
Colombia, Peru, Chile and Mexico. They also, got the highest number of confirmed
cases in Latin America.
2.1 American countries
The number of confirmed cases, varies from each country to another. For
example in Figure 1, we showed the evolution of confirmed cases in top countries
with the major impact. In this case, United States (US), shows an increasing curve
Figure 1.
Evolution of confirmed and deaths in US, India, France, Russia and Brazil. (a) Confirmed cases. (b) Deaths.
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with 31,786,856 confirmed cases until April-20th. Furthermore, in Figure 2, we
plotted the confirmed cases and deaths per million inhabitants. This shows a more
realistic overview.
An interesting point is related to the differences between, confirmed cases and
deaths in some countries. For instance, despite US got the major number of infected
people, it has 1.77 of mortality rate (see Table 1), meanwhile France and Russia got
2.23 and 2.00 respectively. This difference between countries, could be related to
the vaccinations, medical system, population’s social behavior, etc. For example,
meanwhile US has 5262 hospitals, Peru has 390, there is a huge difference. So, it is
not adequate to use just one metric to measure the pandemic impact, we need to
evaluate other metrics in order to understand this COVID-19 pandemic.
Brazil represents another interesting case. Brazil, has the highest public cost of
health services in Latin America but it has 2.48% of death rate (the highest). The
Brazil’s president played a key role in the severity of the virus, at the beginning of
the pandemic, he overestimated the virus.
2.2 Latin American countries
Additionally, in Figures 3 and 4, we shows the confirmed cases and deaths in
Latin American countries. In this case, Mexico has an interesting behavior, this
country got a death rate of 8.85 (see Table 1). According to some researches, the
severity of COVID-19 is positively correlated with several factors, such as age and
coexisting diseases. Moreover, obesity is considered as the main risk factor [11–13].
Obesity, is the key problem in Mexico. According to some surveys in 2000,
2006, 2012, and 2018, the adult obesity increased 42.2%. Moreover, the latest
national survey (2018), concluded that 40.2% female adults and 36.1% male adults
Figure 2.
Evolution of confirmed and deaths per million habitants in US, India, France, Russia and Brazil.
(a) Confirmed cases. (b) Deaths.
Country Death rate (%)a Country Death rate (%)a
US 1.77 Argentina 2.46
India 1.39 Colombia 2.61
France 2.23 Peru 3.52
Russia 2.00 Chile 2.47
Brazil 2.48 Mexico 8.85
aWe compute death rate as the mean of each day from 01 to 01-2021 to 20-04-2021.
Table 1.
Death rate for US, India, France, Russia, Brazil, Argentina, Colombia, Peru, Chile and Mexico.
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suffer from obesity. More alarming, only 23.5% of the adult population had a
healthy weight (BMI<¼ 25kg=m2) [14].
3. Vaccination against COVID-19
In this section, we review the main COVID-19 vaccination projects. The effects
of virus variants and the impact of vaccination in US, India, France, Russia, Brazil,
Argentina, Colombia, Peru, Chile and Mexico.
3.1 COVID-19 variants
Unfortunately, like other viruses, COVID-19 virus evolves over time. Normally,
when the virus replicates, it makes copies of itself with little changes (mutations), a
virus with one or more mutations is call a”variant” of the original virus. Moreover,
the US government inter agency group developed a Variant Classification scheme:
Variant of Interest (VOI), Variant of Concern (VOC) and Variant of High Conse-
quence (VOHC) [15]. In Table 2, we describe each variant.
In Table 3, we resumed the VOI variant of COVID-19, some of them present a
reduced neutralization by antibody treatments and convalescent and post-
vaccination sera [16–19]. In Table 4, VOC variant are presented, for instance
B.1.1.7 and B.1.351 have approximately 50% increased transmission [20, 21].
Figure 3.
Evolution of confirmed and deaths in Argentina, Colombia, Peru, Chile and Mexico. (a) Confirmed cases.
(b) Deaths.
Figure 4.
Evolution of confirmed and deaths per million habitants in Argentina, Colombia, Peru, Chile and Mexico.
(a) Confirmed cases. (b) Deaths.
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Variants B.1.427 and B.1.429 have 20% increased transmissibility [22]. Moreover, all
of VOC variants presents a reduction in neutralization by convalescent and
post-vaccination sera. In order to see a detailed description of each variant, visit:
SARS-CoV-2 Variant Classifications and Definitions [15].
3.2 Vaccination projects
In order to fight this pandemic, global vaccine development efforts have been
accelerated. Clinical development consist of three phases. In Phase I, a small group
of people receive the vaccine. In Phase II, the vaccine is delivered for people whose
characteristics such as age and physical health are similar to which ones the new
vaccine is intended. Finally, in Phase III, the vaccine is given to thousands of people
and tested for efficacy and safety [23].
Approximately, there are 56 verified effective vaccines candidates for COVID-
19, produced in China, North America, Europe and Australia [24]. Furthermore,




VOI “A variant with specific genetic markers that have been associated with changes to
receptor binding, reduced neutralization by antibodies generated against previous
infection or vaccination, reduced efficacy of treatments, potential diagnostic impact, or
predicted increase in transmissibility or disease severity”
VOC “A variant for which there is evidence of an increase in transmissibility, more severe
disease (e.g., increased hospitalizations or deaths), significant reduction in neutralization
by antibodies generated during previous infection or vaccination, reduced effectiveness of
treatments or vaccines, or diagnostic detection failures.”
VOHC “A variant of high consequence has clear evidence that prevention measures or medical
countermeasures (MCMs) have significantly reduced effectiveness relative to previously
circulating variants.”
aThe definition of each variant was extracted from Centers for Disease Control and Prevention [15].
Table 2.
COVID-19 variant classification proposed by US government inter agency group.
Variant name First detected Variant name First detected
B.1.526 United States (New York) -
November 2020
B.1.526.1 United States (New York) -
October 2020
B.1.525 United Kingdom/Nigeria -
December 2020
P.2 Brazil - April 2020
Table 3.
COVID-19 VOI variants detected.
Variant name First detected Variant name First detected
B.1.1.7 United Kingdom P.1 Japan/Brazil
B.1.351 South Africa B.1.427 United States (California)
B.1.429 United States (California)
Table 4.
COVID-19 VOC variants detected.
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Table 5, we present the vaccine types for COVID-19. Finally, in Figure 5, we
present the most important vaccines types against COVID.
3.3 The impact of vaccination
In order to evaluate the impact of vaccination, we analyzed, how the number of
total people vaccinated affects the number of confirmed cases and deaths. We took
data from a data-set that store information about vaccinations [28] and other that
daily store information about the number of confirmed cases and deaths around the
world [29]. For instance, in Figure 6, we present the relation between the total
number of people vaccinated and the total number of confirmed cases and deaths.
In this plot, we evaluated US, India, France, Russia and Brazil. Moreover, we
Vaccine type Description
DNA vaccine “DNA vaccines consist in delivering genes or fragments of it, encoding
immunogenic antigens to the host’s cells by using DNA plasmids as a vector” [25].
Some of these candidates focused in the development of a synthetic DNA-based
SARS-CoV-2 S protein [23].
RNA vaccine RNA vaccines contains RNA, when it is introduced into a tissue, acts as a
messenger RNA (mRNA), then it cause the cells to build the foreign protein and
stimulate an adaptive immune response [26].
Sub-unit vaccine A sub-unit vaccine delivers some antigens to the immune system without
introducing pathogen particles [27]
Vector-based
vaccines
“Viral vectors are commonly utilized together with virus vaccines, in which the
genome of one virus is applied to transmit the antigen of another virus,
facilitating the advancement of platform system for the creation of viruses” [24].
Inactivated SARS-
CoV-2 vaccine
It is another candidate that simulates production of antibodies in rats, mice,




Types of vaccines for COVID-19. Source: [23].
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noticed the differences between some countries (US is the country with the major
number of people vaccinated). Furthermore, we noticed how the number of con-
firmed cases and deaths were reduced since the vaccination started.
Latin American countries, present a similar behavior. In Figure 7, we plotted, how
the number of people vaccinated, affect the number of confirmed cases and deaths. In
this case, Chile and Mexico are the leaders of vaccination in Latin America. Moreover,
the number of confirmed cases and death seems to decrease in this countries.
4. Forecasting COVID-19 confirmed cases
In this section, we evaluated the accuracy of some methods to predict the
confirmed cases of COVID-19. In this case we choose Multiplicative Trend
Exponential Smoothing (MTES) and Long Short-Term Memory (LSTM), as it was
proposed in a previous work [7].
4.1 Multiplicative trend exponential smoothing
The MTES method [30] is usually known to predict non-seasonality data as
modeling with a trend in a multiplicative way, differing from the Hold (additive
trend) method that considered the trend in a additive way [31]. It’s known that on
Figure 6.
The effect of vaccination in total confirmed cases and deaths in US, India, France, Russia and Brazil. (a)
Confirmed cases. (b) Deaths.
Figure 7.
The effect of vaccination in total confirmed cases and deaths in Argentina, Colombia, Peru, Chile and Mexico.
(a) Confirmed cases. (b) Deaths.
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the real world the majority series have multiplicative trends. The MTES method
works with two smoothing parameters designing the local growth rate by
smoothing successive divisions from the local level [32].
4.2 Long short-term memory
LSTM is a recurrent neural network [33]. This network introduces the concepts
of memory cells (Figure 8), this unit is composed of a cell, an input gate, an output
gate and a forget gate. This cell remembers values over time intervals, then the
other gates regulate the flow of information.
Figure 8.
Architecture of memory cell cj and its gate units inj, out j. Source: [33].
Figure 9.
Prediciton of total and daily confirmed cases in United States, using LSTM. (a) Total confirmed cases.
(b) Daily confirmed cases.
Figure 10.
Prediciton of total and daily confirmed cases in India, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
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4.3 Forecasting results
For prediction, we used a Weibull based Long-Short-Term-Memory approach
(W-LSTM) [34]. According to the author of W-LSTM, the model outperformed
ARIMA and other LSTM variants. Moreover, the network got 82% of accuracy. In
Figures 9–12, we show the predictions of total confirmed cases and daily cases for
Figure 12.
Prediciton of total and daily confirmed cases in France, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
Figure 11.
Prediciton of total and daily confirmed cases in Russia, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
Figure 13.
Prediciton of total and daily confirmed cases in Argentina, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
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US, India, Russia and France. Additionally, in Figures 13–17, we present the
predictions for Latin American countries.
In Figure 18a, we plotted the total confirmed cases predictions for US, India,
Russia, France and Brazil, using MTES algorithm. Additionally, In Figure 18b, we
plotted the total confirmed cases predictions for Peru, Argentina, Colombia, Chile
and Mexico. We know that, MTES is usually well used for short time series
Figure 14.
Prediciton of total and daily confirmed cases in Chile, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
Figure 16.
Prediciton of total and daily confirmed cases in Mexico, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
Figure 15.
Prediciton of total and daily confirmed cases in Colombia, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
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prediction. For that reason, the India confirmed cases predictions shows an
increased trend, due to the increasing behavior during the last weeks.
5. Conclusions
The coronavirus COVID-19 pandemic caused strain on all the world getting
abundant deaths and forcing lock downs to contain the spread. However, the
scientific community was not left behind because it was developed a lot of projects
like vaccines candidates, analysis of the confirmed cases, and forecast of confirmed
cases and deaths.
The behavior and evolution of confirmed cases is different for each country.
Moreover, there are several factors that increase or mitigate the COVID-19 evolu-
tion like: population, health system, social behavior and the overestimation of some
authorities. Moreover, in order to evaluate the impact of the pandemic, we need to
evaluate the number of confirmed cases, population, deaths, etc. For instance,
despite US has the major number of confirmed cases, it has a low death rate of
1.77%.
The death rate, is a good metric to evaluate the impact of COVID-19 over
population. For example, we noticed that Mexico has the highest death rate in this
study (8.85%). After review, we found out, that the reason of this high death rate, is
Figure 18.
Prediciton of total and daily confirmed cases in Peru, using LSTM. (a) Predicitons for US, India, Russia,
France and Brazil. (b) Predictions for Peru, Argentinca, Colombia, Chile and Mexico.
Figure 17.
Prediciton of total and daily confirmed cases in Peru, using LSTM. (a) Total confirmed cases. (b) Daily
confirmed cases.
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the percentage of over weighted people in Mexico (40.2% for males and 36.1% for
females). According to researches, obesity is considered the main risk factor of
death by COVID-19.
Additionally, we reviewed the variants and vaccination projects for COVID-19.
Thankfully, we only have VOI and VOC variants. Furthermore, there are several
vaccination projects around the world. Some countries, like US has started a mas-
sive vaccination plan, as a consequence, the number of confirmed cases and deaths,
show a decreasing behavior.
Finally, we made some predictions. We used W-LSTM and MTES to predict the
total and daily confirmed cases in US, India, Russia, France, Argentina, Colombia,














USA United States of America
VOI Variant of Interest
VOC Variant of Concern
VOHC Variant of High Consequence
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